SCHEMBL1614215

SCHEMBL1614215

Cc1[nH]c2ccc(C#CC(C)(O)c3nccs3)cc2c1-c1ccncc1

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MAP3K14 Q99558 17/20 0.57
▸ CHUK O15111 1/20 0.43
▸ PAK4 O96013 1/20 0.43
▸ IMPDH2 P12268 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12743994 0.81 IMPDH2 (0.45) MAP3K14CHUKIMPDH2
SCHEMBL1613149 0.78 MAP3K14 (0.43) MAP3K14PAK4IMPDH2
SCHEMBL1614062 0.73 MAP3K14 (0.56) MAP3K14CHUK
SCHEMBL1613545 0.72 MAP3K14 (0.48) MAP3K14
SCHEMBL1613055 0.72 MAP3K14 (0.46) MAP3K14
SCHEMBL1613056 0.72 MAP3K14 (0.46) MAP3K14
SCHEMBL19629430 0.72 MAP3K14 (0.77) MAP3K14CHUK
SCHEMBL30219545 0.72 MAP3K14 (1.00) MAP3K14
SCHEMBL28986236 0.72 MAP3K14 (1.00) MAP3K14
SCHEMBL1613171 0.71 MAP3K14 (0.49) MAP3K14PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 — — EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 — — US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 — — US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 — — WO disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 MAP3K14 17/4885CHUK 28/4885PAK4 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback